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Abstract. A set of benzophenone-derived bisphosphonium salts was synthesized and assayed for 
lethal activity on the human protozoan parasite Leishmania. A subset of them mostly characterized 
by phosphonium substituents with an intermediate hydrophobicity, inhibited parasite proliferation at 
low micromolar range of concentrations. The best of this subset, 4,4’-bis((tri-n-pentyl 
phosphonium)methyl)benzophenone dibromide, showed a very scarce toxicity on mammalian cells. 
This compound targets complex II of the respiratory chain of the parasite, based on: i) a 
dramatically swollen mitochondrion in treated parasites; ii) fast decrease of cytoplasmic ATP; iii) a 
decrease of the electrochemical mitochondrial potential, and iv) inhibition of the oxygen 
consumption rate using succinate as substrate. Thus this type of compounds represents a new lead in 
the development of leishmanicidal drugs.  
KEYWORDS: bisphosphonium, benzophenone, Leishmania, mitochondria, succinate 
dehydrogenase, chemotherapy. 
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Introduction 
Leishmaniasis encompasses the different clinical manifestations caused by infection with the 
protozoan species belonging to the genus Leishmania. It ranges from the cutaneous form, in many 
cases self-healing, to the visceral leishmaniasis caused by species of the donovani complex, mortal 
if untreated. According to WHO estimations, 12 million people are infected worldwide, with 2 
million new cases per year, from which 500,000 corresponds to the visceral form 
(http://www.who.int/leishmaniasis/burden/en/). Nowadays, chemotherapy is the only effective way 
to fight the disease. Until recently, first-line drugs were constituted almost exclusively by 
pentavalent organic antimonials; aside from their intrinsic high toxicity, their efficacy is threatened 
by rampant resistance.1 In fact, they are progressively being replaced by either liposomal 
formulations of amphotericin B, despite their high cost,2 or miltefosine, the first successful oral 
drug against the visceral form of leishmaniasis.3 Nevertheless, the paucity of new leads in the 
pipeline is a worrisome scenario, raising concern about the near future. Thus, the search and 
development of new leads is an urgent priority.4 
During the screening of in-house made libraries of aromatic and aliphatic dicationic 
derivatives against Trypanosoma brucei,5, 6 the trypanocidal effect of the bisphosphonium 
derivative 4,4’-bis((tri-n-pentylphosphonium)methyl)benzophenone dibromide5 was discovered. 
This compound showed a good trypanocidal activity in vitro with a low DNA-binding affinity,7 in 
contrast to the high affinity of its guanidine counterpart, also trypanocidal. Previously, other authors 
reported for benzyltriphenyl phosphonium derivatives cidal activities on animal infections by 
trypanosomatids such as T. brucei rhodesiense8, 9, T. cruzi (II, Chart 1),10 and Leishmania 
mexicana.
11 However, the literature about the pharmacological applications of phosphonium 
derivatives is relatively scarce, encompassing three major fields mainly. The first one consists of 
phosphonium compounds, such as p-xylylene bis(triphenylphosphonium),12 or 
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poly(methylene)bis(triphenylphosphonium salt (I and III, Chart 1), which showed a marked 
anticholinesterase and anticholinergic activities on Schistosoma mansoni.13 In fact, the 
phosphonium analog of choline is metabolized and incorporated into phospholipids in mammalian 
cells without apparent toxicity.14, 15  
A second group of phosphonium compounds is characterized by a strong amphipathic 
character endowed by the presence of, at least, one long alkyl chain substituent. They were 
extensively used as biocides, either in monomeric16 or polymeric form.17-19 They work as cationic 
detergents, disrupting the cell membrane. Some specificity for this process is achieved by profiting 
the higher anionic character of cell membranes on prokaryotes and lower eukaryotes (reviewed in 
20).  
Finally, some phosphonium derivatives act as lipophilic ions with a delocalized charge and 
enhanced hydrophobicity. These characteristics afford their transfer across biological membranes 
despite their cationic nature, with a privileged accumulation in organelles with a strong 
electrochemical potential, such as mitochondria.21-23 Hence, the massive accumulation of these 
lipophilic cations into mitochondria, may by itself lead to mitochondrial dysfunction, which in turn 
will trigger the apoptotic mitochondrial pathway (reviewed in 24). This is especially relevant in 
transformed cells, with a higher ∆Ψm
a than their non-transformed counterparts.25, 26 As far as 
Leishmania is concerned, the above mentioned properties of phosphonium derivatives are 
particularly relevant if one consider the strong anionic character of the parasite plasma membrane27 
and the key role of mitochondria in the bioenergetics of this parasite. This could in turn represent a 
target for antileishmanial chemotherapy. To assess this hypothesis, we have synthesized and 
assayed a number of bisphosphonium benzophenone derivatives bearing different substituents on 
the phosphonium moieties (IV, Chart 1). As the DNA-binding properties of some of these 
compounds can not fully account for their trypanocidal effects, and likely for their leishmanicidal 
activities,7 we set out to study other alternative mechanisms. In tune with the aforementioned 
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properties of this class of compounds, their effects on plasma membrane integrity and mitochondrial 
functionality in Leishmania were studied in detail. By complementary bioenergetics and 
morphological approaches, we have defined the impairment of mitochondrial functionality, as the 
basis for the leishmanicidal mechanism of bisphosphonium benzophenones, exemplified by 7, the 
best within this series. This compound severely impaired mitochondrial ATP synthesis through 
inhibition of the respiratory complex II (succinate dehydrogenase). 
 
Results 
Chemistry. The bisphosphonium salts 1-19 were synthesized by reaction of 4,4’-
bisbromomethylbenzophenone with the corresponding phosphine in either anhydrous DMF or 
anhydrous toluene (Scheme 1). The bisphosphonium salts were isolated with satisfactory yields by 
crystallization from the reaction mixture. All the starting phosphines were commercially available 
except tripentylphosphine which was prepared as previously reported.5 The substitution pattern (R1, 
R2, and R3) of compounds 1-19 is shown in Table 1. 
Cytotoxicity against Leishmania Parasites. The reduction of MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] by living cells constitutes a suitable 
parameter to assess the viability in an extensive range of cell lines, including Leishmania.28 As 
such, the capability of bisphosphonium salts to inhibit MTT reduction by Leishmania parasites was 
used to assess the potential leishmanicidal activity of these compounds. The results were compiled 
in Table 1. From the initial set of 19 bisphosphonium compounds, 11 showed a LC50 on L. 
donovani promastigotes at the low micromolar range. Under identical criteria, the same subset 
resulted active on L. pifanoi axenic amastigotes, except 19, with a LC50 higher than 50 µM, the cut-
off established in the present study to select the active candidates (Table 1). Interestingly, 
amastigotes, the pathological form of the parasite in vertebrates, resulted more susceptible than 
promastigotes, with the sole exception of compound 14 and the aforementioned 19. The results 
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underscore certain structural features modulating the leishmanicidal activity. For compounds with 
homoalkyl groups, the activity was restricted to those with a narrow range of substituents, from 5 to 
8 carbon length, suggesting an important role for hydrophobicity, tightly limited in values. 
Compound 7, with n-pentyl substituents, showed the highest potency. The combination of two alkyl 
groups plus an aromatic substituent was not enough to recover activity for methyl (10) or ethyl (11) 
substituents, but a better activity was achieved when two phenyl groups (13, 14) or cyclohexyl 
substituents were present (compound 12). The triphenyl phosphonium (15) or diphenyltolyl (17, 18) 
compounds showed activities very close to the n-pentyl substituted compound. In particular, the 
diphenyl-p-tolyl analogue (18) displayed the second best activity of the whole series. Inclusion of a 
heterocycle was well tolerated for 2-pyridyl (16), but impaired activity in more than one log order 
for furanyl (19). As compound 7 turned out to be the most active molecule, both on promastigotes 
and amastigotes, its toxicity on mammalian cells was assayed. The LC50 of 7 on mouse peritoneal 
macrophages was 28.6 ± 4.8 µM. This represents a therapeutic index of 28, defined as the ratio 
between the respective LC50s for mammalian cells and for amastigotes, the pathological form in 
mammals. According to its highest leishmanicidal activity and scarce toxicity on mammalian cells, 
compound 7 was selected for the subsequent set of assays dealing with its mechanism of action.  
Decrease of Intracellular ATP Levels. The maintenance of an adequate intracellular ATP 
level is essential for cellular homeostasis. The in vivo luminescence of 3-Luc promastigotes affords 
a real-time monitorization of changes in the cytoplasmic ATP pool.29 Accordingly, compound 7 
caused a drop of the luminescence of the 3-Luc strain in a concentration-dependent manner, 
reaching the end-point 10-15 min after addition (Figure 1). Altogether, these results suggest a 
decrease of the cytoplasmic ATP pool caused by 7. 
Maintenance of Plasma Membrane Integrity. The drop of intracellular ATP observed in 
the previous assay can be caused either by inhibition of mitochondrial ATP synthesis, essential in 
the bioenergetics of Leishmania, otherwise by permeabilization of the parasite plasma membrane, 
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leading to ATP release or its futile hydrolysis by ionic pumps, in an attempt to recover the initial 
ionic gradients. The latter alternative was examined by monitoring the entrance of the vital dye 
SYTOX green. Even at 25 µM, i.e. a 25-fold higher concentration than its LC50, compound 7 was 
unable to produce any significant increase of SYTOX green fluorescence, ruling out damage to the 
plasma membrane integrity (data not shown). 
Morphological Alterations Induced by Compound 7. In a further step, the morphological 
damage inflicted to the promastigotes by compound 7 was visualized by transmission electron 
microscopy. Electron micrographs showed an extremely swollen mitochondrion for parasites 
treated with 7 at 5 µM (Figure 2). This organelle appeared as a huge, electron translucent vacuole, 
occupying a large fraction of the intracellular space. In fact, mitochondrion was only identified by 
the presence of the kinetoplast, the mitochondrial network of concatenated DNA circles, 
characteristic of trypanosomatids. Furthermore, the plasma membrane appeared mostly intact, 
which confirmed the above results with SYTOX green. 
Effect on Mitochondrial Functionality. The cumulative evidence of the results obtained by 
the two previous techniques, prompted us to get a deeper insight into mitochondrial functionality. In 
a first step, we examined the variation of ∆Ψm, essential to drive the mitochondrial ATP synthesis, 
assessed by rhodamine 123 accumulation in promastigotes, and monitored by cytofluorometry. The 
∆Ψm-driven accumulation of rhodamine showed a consisting decreasing trend after incubation with 
growing concentrations of 7 (Figure 3). The same result was obtained when the incubation was 
carried out for 4 h in HBSS, conditions used for luminescence and cytotoxicity (data not shown). 
Rhodamine 123 accumulation also decreased around 50% for most of the remaining leishmanicidal 
benzophenone-derived bisphosphonium compounds at their respective LC50 (Table 1), confirming 
mitochondrial damage inflicted by these drugs. Nevertheless, compounds 13, 14 and 16, did not 
follow the same trend (Table 1), suggesting alternative targets.  
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In a step forward, we set out to define the molecular target of 7 in the mitochondrial ATP 
synthesis. To afford free access of specific substrates and inhibitors to the different complexes of 
the respiratory chain, digitonin-permeabilized parasites were used. The integrity of the inner 
mitochondrial membrane was preserved, as after ADP addition, the respiration increased recovering 
state 3, in which ADP is not longer the limiting substrate for oxidative phosphorylation. At this 
state, oxygen consumption rate of digitonin-permeabilized parasites was 9.4 nmol × min-1 × 10-8 
cells (Figure 4B). The addition of 16 µM of compound 7 to digitonized parasites leads to a full 
inhibition of the oxygen consumption rate using succinate as substrate (Figure 4B). Addition of 10 
µM FCCP, a mitochondrial uncoupler, did not revert this inhibition, ruling out any specific 
inhibition of 7 on F1F0-ATPase (Figure 4A). In contrast, addition of TMPD-ascorbate, an electron 
donor to cytochrome c30 restored the oxygen consumption rate at 50% of the initial value (Figure 
4B). This excludes cytochrome c oxidase (complex IV) as the site of inhibition, and circumscribes 
the potential target upstream cytochrome c (Scheme 2). The oxygen consumption rate inhibited by 7 
was partially (33%) reinstated upon addition of 6.7 mM α-glycerophosphate (data not shown), a 
substrate of complex I.30 Consequently, this result ruled out complexes I and III as targets for 7, and 
supports complex II as the more likely target for this drug. To verify this hypothesis the succinate-
dependent respiration was inhibited with malonate at the level of complex II, and oxygen 
consumption was allowed to proceed with α-glycerophosphate as the sole substrate through 
complex I. Under these conditions, i.e. without a functional complex II, compound 7 did not exert 
any inhibitory effect on the α-glycerophosphate–dependent respiration (Figure 4C), pointing at 
complex II as the main target within oxidative phosphorylation. 
Leishmania Killing Involves an Apoptotic Process. Since the mitochondrion plays a 
pivotal role in the onset of apoptosis in Leishmania, the induction of apoptosis by compound 7 was 
investigated. 
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Overnight incubation of promastigotes with different concentrations of compound 7, lead to 
an increase in the sub-G1 peak region, accounting for fragmented chromatin, hence of apoptosis 
(Figure 5). The percentage of promastigotes with a PI fluorescence in the peak region typical of 
apoptotic cells was 22% at the LC50, while in parasites treated with miltefosine, a typical apoptosis 
inducer in Leishmania31, the percentage was 25% at 15 µM, its LC50 on promastigotes (Figure 5). 
 
Discussion.  
The choice of phosphonium substituents with moderate hydrophobicity led to compounds 
with an intermediate lipophilicity, capable to traverse the plasma membrane and accumulate in 
organelles driven by electrical potentials.24 According to this hydrophobicity criteria for the 
substituents, from the set of compounds tested, those with leishmanicidal activity belong to this 
group. The substituents are medium length alkyl chains (5-8 carbons), aryl groups, or a combination 
of both. Nevertheless, the literature regarding these compounds is mostly based on the presence of a 
single phosphonium group in the molecule. Actually, the uptake of dications may be impaired by 
the double charge present in the molecule. In fact, the desolvatation process (i.e., energy required to 
remove solvating water molecules) is the main energy demand to move a cation from the aqueous 
medium to the hydrophobic lipid membrane.21 In practical terms, the bisphosphonium cations 
require a higher threshold hydrophobicity than monophosphonium compounds to traverse the 
membrane21 which for the set of compounds assayed was provided by the benzophenone scaffold 
connecting the two phosphonium moieties. As the entrance of the vital dye SYTOX green into 
parasites is nil, even at concentrations higher than those required for full lethality, plasma 
membrane permeabilization was ruled out as a major cause of parasite killing. Thereby, the lethal 
activity must involve intracellular targets, thus, uptake of compound 7 and other active compounds 
by the parasite. Accordingly, the balance of hydrophobicity with charge, required for the 
translocation across the membrane, is finely tuned. In fact, changes in the overall polarity of the 
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whole molecule, achieved with a single incorporation of a heterocycle with slightly higher polarity 
than the phenyl substituent, impaired (2-pyridinyl, 16), or almost abrogated (2-furanyl, 19) 
leishmanicidal activity. The same happened when hydrophobicity was decreased for short alkyl 
substituents (1-6, 10-11). This exquisite modulation by subtle changes in the hydrophobicity of 
phosphonium substituents has been employed to optimize the mitochondrial uptake of MitoQ, 
consisting in an antioxidant ubiquinone coupled to a phosphonium group.31,32  
The cellular uptake and accumulation for phosphonium compounds is driven by electrical 
potential;22 hence the plasma membrane potential and, in a further step the higher ∆Ψm of the 
mitochondrion will lead to a massive accumulation of these compounds in this organelle.23, 24, 33 
Although in this work we did not attempt to define the intracellular distribution of compound 7, 
from the experimental results it was concluded beyond reasonable doubt that mitochondria 
constitutes an essential target for that compound. This is demonstrated by morphological data, 
obtained from micrographs were the mitochondrion of Leishmania appeared dramatically swollen 
in parasites treated with 7. This result was validated from a functional perspective; 7 provokes a 
prominent decrease of cytoplasmic ATP level, as assessed in real-time by the rapid decay of 
luminescence of living 3-Luc parasites.29 Once the leakage of intracellular ATP or its enhanced 
hydrolysis associated to membrane permeabilization were discarded as the reason for these effects, 
impairment of ATP synthesis, essentially of mitochondrial origin in Leishmania, came out as the 
most feasible target for compound 7. In fact, this compound causes the decrease of ∆Ψm, which 
drives mitochondrial ATP synthesis, a trend also observed for most of the compounds, for which 
leishmanicidal effect is associated with inhibition of rhodamine 123 accumulation. 
 Finally, the mitochondrial dysfunction created by 7 was unequivocally pinpointed to the 
inhibition of complex II, according to the systematic dissection of the functionality of the whole set 
of components involved in the oxidative phosphorylation process.  
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According to experimental data provided by other authors, we surmise two major 
alternatives to account for the inhibition of complex II; either, an unspecific effect due to a general 
mitochondrial dysfunction, otherwise, produced by a specific effect of 7 on complex II . 
Under the hypothesis of an unspecific origin for the inhibition of complex II by 7, this would 
be likely due to the perturbation of the biophysical parameters of the inner mitochondrial membrane 
after massive ∆Ψm-driven insertion of 7, as a lipophilic phosphonium compound. In fact, the 
specific tumoricidal activity of phosphonium compounds was based on their larger accumulation in 
mitochondria, due to the significant higher ∆Ψm in transformed- versus non-transformed cells.
24, 34-
36 For Leishmania, the ∆Ψm values reported are rather similar to those for mammalian cells (-150 
mV in L. donovani promastigotes37 vs -140 to -180 mV in mammalian cells38). Although plasma 
membrane potential is higher in Leishmania (ca -100 to -110 mV)39-41 than in many typical 
eukaryotic resting cells (-30 to -60 mV),42 the only predicted effect will be a faster transfer of 
bisphosphonium compounds from the external medium into the intracellular space. Nevertheless, 
the final mitochondrial accumulation of 7, driven solely by ∆Ψm., will be similar in both types of 
cells. Additional facts to discard an unspecific effect are provided by the integrity of the inner 
mitochondrial membrane throughout the time span of the experiment, as well as preservation of the 
functionality of the rest of the components within the respiratory chain. This is evidenced by the 
unaltered oxygen consumption rate obtained in the presence of 7, when the system was artificially 
fed with substrates outside complex II, i.e. α-glycerophosphate and TMPD-ascorbate. 
Hence, a specific inhibition of compound 7 on the mitochondrial complex II is the most feasible 
scenario to account for its leishmanicidal activity. In cancer cells, other lipophilic cations such as 
rhodamine 123 or AA-1 (thiopyrilium) work by specific inhibition, in this case the F1F0-ATPase.
25 
Drugability of complex II in Leishmania has been reported for other compounds43, 44 also leading to 
apoptosis of the parasite,43 as happens with 7. 
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The uniqueness of the complex II of Leishmania as target for 7, may be disputed on the 
basis of i) its dicationic character will presumably afford binding to either nuclear or kinetoplast 
DNA, as described for its guanidine homolog, but this possibility was ruled out on the grounds of 
the poor affinity of 7 for DNA.7 ii) Compound 7 is active on the bloodstream forms of the African 
trypanosome T. b. rhodesiense.5 It is well established that the bioenergetic requirements of this form 
of parasite are fulfilled by glycolysis rather than through oxidative phosphorylation,45 as 
Leishmania does. Nevertheless, for this trypanosomal form the maintenance of a rudimentary 
mitochondrion with a residual ∆Ψm is essential, although sustained by the electrogenic activity of 
mitochondrial ATPase46 without the concourse of cytochrome-containing complexes. Altogether 




Although the potential of phosphonium compounds as leishmanicidal drugs has been previously 
described for African and American trypanosomes, and very succintly mentioned for L. braziliensis 
and L. mexicana, this work demonstrates the feasibility of benzophenone-derived bisphosphonium 
salts as new leishmanicidal lead compounds. A fine modulation of the activity and specificity was 
achieved by the adequate selection of substituent based on their hydrophobicity. Two additional 
facts stressed this assertion; first the higher susceptibility of amastigotes, as the pathological form of 
the parasite in vertebrates, over promastigote; and secondly, compound 7 acts over complex II of 
the mitochondrial respiratory chain. The importance of this target for Leishmania is highlighted by 
the total dependence of this parasite on mitochondrial ATP synthesis to fulfill its bioenergetic 
requirements. Furthermore, in quantitative terms, complex II is the main gate for the metabolic 
feeding of the respiratory chain. All these items make highly attractive the exploitation of 
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bisphosphonium salts as new leishmanicidal leads. Further progress in SAR studies is currently 
ongoing.  
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Experimental Section 
Chemistry. All dry solvents were purchased from Aldrich or Fluka in Sure/Seal bottles. All 
reactions requiring anhydrous conditions or an inert atmosphere were performed under a positive 
pressure of N2. All reactions were monitored by HPLC–MS. 
1H and 13C NMR spectra were 
recorded on a Bruker Advance 300 or Varian Inova 400 spectrometer. Chemical shifts of the 1H 
NMR spectra were internally referenced to the residual proton resonance of the deuterated solvents: 
CDCl3 (7.24 ppm) and DMSO (δ 2.5 ppm). J values are given in Hz. Chemical shifts of the 13C 
NMR spectra were referenced to the carbon resonance of the deuterated solvents: CDCl3 (77.23 
ppm) and DMSO (δ 39.51 ppm). Melting points were determined in open capillary tubes with a 
SMP3–Stuart Scientific apparatus and are uncorrected. The solvent used for crystallization is 
indicated between brackets. The purity of the compounds was ≥ 95% as assessed by combustion 
analysis or HPLC. Elemental analysis was performed on a Heraeus CHN–O Rapid analyzer. 
Analytical results were within ± 0.4% of the theoretical values unless otherwise noted. Analytical 
HPLC–MS was run with a Waters Sunfire C18–3.5 µm (4.6×50mm) column on a Waters 2695 
separation module coupled with a Waters Micromass ZQ spectrometer using electrospray ionization 
(ES+). The following HPLC conditions were used: column temperature = 30 ºC, gradient time = 5 
min, H2O/CH3CN (90:10 → 0:100) (HCO2H 0.1%), flow rate = 1 mL/min, UV detection: diode 
array (λ = 190−400 nm). HRMS spectra were recorded on a QTOF 6520 Agilent Technologies 
mass spectrometer. 
General procedure for the synthesis of the bisphosphonium salts 1–19: a Kimax tube was 
charged with 4,4’-bis(bromomethyl)benzophenone5 (100 mg, 0.272 mmol) and flushed with argon. 
Anhydrous DMF (3 mL) was added followed by the phosphine (1.1 mmol, 4 equiv). The tube was 
flushed with argon, stopped, and the reaction mixture was stirred at 110 ºC for 20h. Different 
workup procedures were used depending on whether the product precipitated from the reaction 
mixture or not. Workup I: the reaction was allowed to cool to room temperature and the precipitated 
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product was collected by filtration, rinsed successively with toluene and Et2O, and dried under 
vacuum. Workup II: the reaction mixture was transferred to a flask. Then, toluene (10 mL) was 
added to precipitate the product. The flask was stored in the fridge overnight. The supernatant was 
removed and the precipitate rinsed with toluene. Et2O (10 mL) was added and the precipitate was 
triturated with a spatula. The solid was collected, rinsed with Et2O and dried under vacuum.  
The synthesis of compounds 75 and 1547, 48 was reported before. We report here for the first time the 
detailed 1H and 13C NMR spectroscopic data for 15. 
4,4'-bis((trimethylphosphonio)methyl)benzophenone dibromide (1). The reaction was carried 
out following the general procedure with trimethylphosphine (1M in toluene). The product was 
obtained as a colorless solid (82%) following workup I procedure; mp 208–213 ºC with previous 
softening (DMF/toluene); 1H NMR (300 MHz, DMSO) δ 7.81 (d, J = 7.8, 4H, ArH), 7.52 (dd, J = 
8.2, 2.3, 4H, ArH), 3.97 (d, J = 17.5, 4H, PhCH2P), 1.86 (d, J = 14.7, 18H, CH3).
 13C NMR (75 
MHz, DMSO) δ 195.21 (CO), 136.59 (d, J = 3.7, Cq), 135.01 (d, J = 9.1, Cq), 130.77 (d, J = 3.2, 
CH), 130.49 (d, J = 5.2, CH), 29.84 (d, J = 48.2, CH2), 7.43 (d, J = 54.0, CH3). LRMS (ES
+) m/z 
359.11 [(M-H)+], 180.23 [M2+, 100%]. ESI-HRMS m/z 359.1696 (M-H)+ (C21H29OP2 requires 
359.1688). HPLC ≥ 95%. 
4,4'-bis((triethylphosphonio)methyl)benzophenone dibromide (2). The reaction was carried out 
following the general procedure using dry toluene instead of DMF, and triethylphosphine (1M in 
THF). The yellow precipitate was collected by filtration and rinsed with toluene. Recrystallization 
from hot DMF afforded 2 as a yellowish solid (58%); mp 284–288 ºC with previous softening 
(DMF); 1H NMR (300 MHz, DMSO) δ 7.79 (d, J = 8.0, 4H, ArH), 7.58 (dd, J = 8.0, 2.0, 4H, ArH), 
4.02 (d, J = 16.1, 4H, PhCH2P), 2.26 (dq, J = 15.2, 7.6, 12H, CH2CH3), 1.14 (dt, J = 18.3, 7.6, 18H, 
CH3). 
13C NMR (75 MHz, DMSO) δ 195.05 (CO), 136.54 (d, J = 3.4, Cq), 134.85 (d, J = 8.5, Cq), 
130.76 (d, J = 6.7, CH), 130.68 (d, J = 3.9, CH), 24.92 (d, J = 44.1, PhCH2P), 11.13 (d, J = 48.1, 
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CH2), 5.58 (d, J = 5.4, CH3). LRMS (ES
+) m/z 443.25 [(M-H)+], 222.32 [M2+, 100%]. ESI-HRMS 
m/z 443.2634 (M-H)+ (C27H41OP2 requires 443.2627). HPLC ≥ 95%. 
4,4'-bis((tripropylphosphonio)methyl)benzophenone dibromide (3). The reaction was carried 
out following the general procedure using dry toluene instead of DMF, and tri-n-propylphosphine. 
The reaction was allowed to cool to room temperature whereupon a yellow sticky residue was 
precipitated on the walls of the tube. The supernatant was discarded and the precipitate dissolved in 
a little DMF. Then, 3 was obtained as a yellowish solid (61%) following workup I procedure; mp 
90–95 ºC with previous softening (DMF/toluene); 1H NMR (300 MHz, DMSO) δ 7.80 (d, J = 8.1, 
4H, ArH), 7.57 (dd, J = 8.1, 1.9, 4H, ArH), 4.01 (d, J = 16.0, 4H, PhCH2P), 2.24 – 2.17 (m, 12H, 
PCH2CH2), 1.53 (dp, J = 14.9, 7.3, 12H, CH2CH3), 1.01 (dt, J = 7.3, 1.2, 18H, CH3). 
13C NMR (75 
MHz, DMSO) δ 194.64 (CO), 136.60 (d, J = 3.4, Cq), 134.92 (d, J = 8.6, Cq), 130.74 (d, J = 2.8, 
CH), 130.64 (d, J = 5.0, CH), 25.93 (d, J = 43.9, PhCH2P), 20.01 (d, J = 46.2, PCH2), 15.64 (d, J = 
16.7, CH2), 15.06 (d, J = 4.3, CH3). LRMS (ES
+) m/z 527.33 [(M-H)+], 264.35 [M2+, 100%]. Anal. 
Calcd. (C33H54Br2OP2 • 2 H2O): C, 54.70; H, 8.07. Found: C, 54.56; H, 7.90. 
4,4'-bis((triisopropylphosphonio)methyl)benzophenone dibromide (4). The reaction was carried 
out following the general procedure using dry toluene instead of DMF, and tri-isopropylphosphine 
(technical grade 90%). Compound 4 was obtained as a yellowish solid (59%) following workup I 
procedure and recrystallization from DMF; mp 277–278 ºC (DMF); 1H NMR (300 MHz, DMSO) δ 
7.78 (d, J = 8.1, 4H, ArH), 7.61 (dd, J = 8.1, 1.7, 4H, ArH), 4.20 (d, J = 14.9, 4H, CH2P), 3.05 – 
2.78 (m, 6H, CH), 1.31 (dd, J = 15.9, 7.2, 36H, CH3). 
13C NMR (75 MHz, DMSO) δ 194.78 (CO), 
136.43 (d, J = 2.8, Cq), 135.55 (d, J = 8.0, Cq), 131.07 (d, J = 4.6, CH), 130.75 (CH), 22.04 (d, J = 
40.4), 20.50 (d, J = 41.0), 16.63 (d, J = 3.2, CH3). LRMS (ES
+) m/z 527.27 [(M-H)+]. Anal. Calcd. 
(C33H54Br2OP2 • 1/3 H2O• 1/3 C3H7NO): C, 56.80; H, 7.99, Br, 22.23. Found: C, 56.64; H, 8.38; Br, 
22.08. 
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4,4'-bis((tributylphosphonio)methyl)benzophenone dibromide (5). The reaction was carried out 
following the general procedure with tri-n-butylphosphine. Compound 5 was obtained as a beige 
solid (87%) following workup II procedure; mp 154.2–157.7 ºC with previous softening (Et2O); 
1H 
NMR (300 MHz, DMSO) δ 7.79 (d, J = 7.9, 4H, ArH), 7.57 (d, J = 7.9, 4H, ArH), 4.01 (d, J = 16.0, 
4H, PhCH2P), 2.19 (br m, 12H, PCH2CH2), 1.41 (br m, 24H, CH2CH2), 0.90 (t, J = 6.8, 18H, CH3). 
13C NMR (75 MHz, DMSO) δ 195.12 (CO), 136.64 (d, J = 3.4, Cq), 134.98 (d, J = 8.4, Cq), 130.67 
(CH), 130.61 (CH), 25.90 (d, J = 43.8, PhCH2P), 23.70 (d, J = 15.9, CH2), 22.92 (d, J = 4.5, CH2), 
17.79 (d, J = 46.8, PCH2),13.60 (CH3). LRMS (ES
+) m/z 611.35 [(M-H)+], 306.38 [M2+, 100%]. 
ESI-HRMS m/z 611.4507 (M-H)+ (C39H65OP2 requires 611.4505). HPLC ≥ 95%. 
4,4'-bis((triisobutylphosphonio)methyl)benzophenone dibromide (6). The reaction was carried 
out following the general procedure with tri-isobutylphosphine. Compound 6 was obtained as an 
off-white solid (56%) following workup II procedure; mp 79–85 ºC (DMF/toluene); 1H NMR (300 
MHz, DMSO) δ 7.80 (d, J = 8.0, 4H, ArH), 7.60 (dd, J = 8.0, 1.8, 4H, ArH), 4.09 (d, J = 15.6, 4H, 
PhCH2P), 2.26 (dd, J = 13.1, 6.1, 12H, PCH2CH), 2.12 (m, J = 6.1, 6H, CH), 1.02 (d, J = 6.6, 36H, 
CH3).
 13C NMR (75 MHz, DMSO) δ 195.13 (CO), 136.63 (d, J = 3.3, Cq), 134.91 (d, J = 8.7, Cq), 
131.00 (d, J = 4.8, CH), 130.64 (d, J = 2.3, CH), 28.00 (d, J = 43.0, CH2P), 27.62 (d, J = 42.8, 
CH2P), 24.88 (d, J = 8.6, CH3), 23.03 (d, J = 4.6, CH2). LRMS (ES
+) m/z 611.37 [(M-H)+], 306.33 
[M2+, 100%]. ESI-HRMS m/z 611.4514 (M-H)+ (C39H65OP2 requires 611.4505). HPLC = 92%. 
4,4'-bis((tricyclohexylphosphonio)methyl)benzophenone dibromide (8). The reaction was 
carried out following the general procedure with tricyclohexylphosphine. The reaction was 
concentrated to ca. 1 mL resulting a yellowish oil that was diluted with toluene (10 mL). Addition 
of Et2O (10 mL) caused precipitation of an oily residue. The flask was stored in the refrigerator 
overnight. The supernatant was removed and the oily precipitate was rinsed with toluene. Et2O (10 
mL) was added to the oily precipitate which was triturated with a spatula to afford 8 as a colorless 
solid (75%); mp 151–156 ºC with previous softening (DMF/toluene/Et2O); 
1H NMR (300 MHz, 
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DMSO) δ 7.79 (d, J = 7.7, 4H, ArH), 7.57 (d, J = 7.7, 4H, ArH), 4.17 (d, J = 14.7, 4H, PhCH2P), 
2.58 (m, 6H, PCH), 2.15 – 1.14 (m, 60H, CH2).
 13C NMR (75 MHz, DMSO) δ 195.09 (CO), 136.64 
(Cq), 135.79 (d, J = 7.9, Cq), 131.03 (d, J = 4.5, CH), 130.72 (CH), 29.89 (d, J = 39.4, PCH2), 26.41 
(CH2), 26.24 (CH2), 25.31 (CH2), 21.80 (d, J = 39.9, PCH). LRMS (ES
+) m/z 767.44 [(M-H)+], 
383.99 [M2+, 100%]. ESI-HRMS m/z 767.5451 (M-H)+ (C51H77OP2 requires 767.5444). HPLC ≥ 
95%. 
4,4'-bis((trioctylphosphonio)methyl)benzophenone dibromide (9). The reaction was carried out 
following the general procedure with tri-n-octylphosphine (technical grade 90%). Compound 9 was 
isolated as a yellowish hygroscopic solid (33%) following the same workup as described for 8; 1H 
NMR (300 MHz, CDCl3) δ 7.57 (m, 4H, ArH), 7.45 (d, J = 7.6, 4H, ArH), 4.66 (d, J = 16.1, 4H, 
PhCH2P), 2.31 (br m, 12H, PCH2CH2), 1.7 – 1.1 (m, 72H, (CH2)6), 0.79 (t, J = 5.5, 18H, CH3). 
13C 
NMR (75 MHz, CDCl3) δ 194.53, 136.43, 134.37 (d, J = 9.1), 130.72, 130.64, 31.77, 30.99 (d, J = 
14.8), 29.05 (d, J = 6.6), 22.70, 22.02 (d, J = 4.7), 19.71 (d, J = 24.1), 18.94, 14.18. LRMS (ES+) 
m/z 947.86 [(M-H)+], 473.96 [M2+, 100%]. ESI-HRMS m/z 473.4093 (M-H)2+ (C63H112OP2 requires 
473.4094). HPLC ≥ 95%. 
4,4'-bis((dimethylphenylphosphonio)methyl)benzophenone dibromide (10). The reaction was 
carried out following the general procedure with dimethylphenylphosphine. Compound 10 was 
obtained as an off-white solid (79%) following workup II procedure; mp 95–100 ºC (decomp.); 1H 
NMR (300 MHz, DMSO) δ 8.05 – 7.89 (m, 4H, ArH), 7.82 (dd, J = 7.6, 5.7, 2H, ArH), 7.76 – 7.61 
(m, 8H, ArH), 7.31 (dd, J = 8.3, 2.4, 4H, ArH), 4.25 (d, J = 17.0, 4H, PhCH2P), 2.25 (d, J = 14.5, 
12H, CH3). 
13C NMR (75 MHz, DMSO) δ 195.15 (CO), 136.56 (d, J = 3.9, Cq), 134.62 (d, J = 2.6, 
Cq), 134.51 (d, J = 9.1), 132.31 (d, J = 10.0, CH), 130.58 (m, CH), 129.79 (d, J = 12.4, CH), 120.75 
(d, J = 84.2, Cq), 30.83 (d, J = 46.5, CH3), 6.42 (d, J = 54.5, CH3). LRMS (ES
+) m/z 483.13 [(M-
H)+], 242.23 [M2+, 100%]. ESI-HRMS m/z 483.2000 (M-H)+ (C31H33OP2 requires 483.2001). HPLC 
= 94%. 
  19 
4,4'-bis((diethylphenylphosphonio)methyl)benzophenone dibromide (11). The reaction was 
carried out following the general procedure with diethylphenylphosphine. Compound 11 was 
obtained as an off-white solid (60%) following workup II procedure; mp 69–76 ºC (DMF/toluene); 
1H NMR (300 MHz, DMSO) δ 8.04 – 7.78 (m, 6H, ArH), 7.72 (dt, J = 7.4, 3.7, 4H, ArH), 7.64 (d, J 
= 8.0, 4H, ArH), 7.29 (dd, J = 8.2, 2.1, 4H, ArH), 4.37 (d, J = 16.0, 4H, PhCH2P), 2.81 – 2.59 (m, 
8H, CH2CH3), 1.16 (dt, J = 19.2, 7.5, 12H, CH3).
 13C NMR (75 MHz, DMSO) δ 195.01 (CO), 
136.51 (d, J = 3.6, Cq), 134.88 (d, J = 2.6, Cq), 134.27 (d, J = 8.5), 132.99 (d, J = 8.7), 130.60 (d, J 
= 5.6, CH), 130.52 (CH), 130.13 (d, J = 11.7, CH), 117.22 (d, J = 79.4; Cq), 26.74 (d, J = 44.7, 
CH2P), 11.55 (d, J = 49.3, CH2P), 5.76 (d, J = 5.0, CH3). LRMS (ES
+) m/z 539.2 [(M-H)+], 270.29 
[M2+, 100%]. ESI-HRMS m/z 539.2635 (M-H)+ (C35H41OP2 requires 539.2627). HPLC = 92%. 
4,4'-bis((dicyclohexylphenylphosphonio)methyl)benzophenone dibromide (12). The reaction 
was carried out following the general procedure with dicyclohexylphenylphosphine. Workup II 
procedure followed by recrystallization from EtOH/Et2O afforded 12 as a yellowish solid (33%); 
mp > 300 ºC (decomp.); 1H NMR (400 MHz, CDCl3) δ 8.10 (t, J = 8.7, 4H, ArH), 7.67 (m, 6H, 
ArH), 7.12 (brs, 8H, ArH), 5.33 (d, J = 15.2, 4H, PhCH2P), 3.09 (m, 4H, PCH), 2.25 – 1.00 (m, 
40H, CH2).
13C NMR (101 MHz, CDCl3) δ 194.27 (CO), 135.70 (d, J = 3.2), 135.12 (d, J = 8.7), 
134.32 (d, J = 2.3), 134.18 (d, J = 7.6), 130.83 (d, J = 4.8), 130.24, 130.10 (d, J = 5.9), 115.35 (d, J 
= 73.7, Cq), 31.28 (d, J = 42.3, PCH2), 26.73, 26.55, 25.74, 24.82 (d, J = 40.7, PCH2). LRMS (ES
+) 
m/z 755.36 [(M-H)+], 378.21 [M2+, 100%]. ESI-HRMS m/z 755.4508 (M-H)+ (C51H65OP2 requires 
755.4505). HPLC ≥ 95%. 
4,4'-bis((diphenylmethylphosphonio)methyl)benzophenone dibromide (13). The reaction was 
carried out following the general procedure with methyldiphenylphosphine. Compound 13 was 
obtained as an off-white solid (71%) following workup II procedure; mp 110–113 ºC (decomp); 1H 
NMR (300 MHz, DMSO) δ 7.97 (dd, J = 12.8, 7.3, 8H, ArH), 7.86 (dd, J = 8.0, 6.2, 4H, ArH), 7.74 
(td, J = 7.6, 3.4, 8H, ArH), 7.61 (d, J = 7.9, 4H, ArH), 7.38 – 7.26 (m, 4H, ArH), 4.82 (d, J = 16.9, 
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4H, PhCH2P), 2.63 (d, J = 14.1, 6H, CH3); 
13C NMR (75 MHz, DMSO) δ 195.03 (CO), 136.60 (d, J 
= 3.8), 135.02 (d, J = 2.5), 133.85 (d, J = 8.3), 133.06 (d, J = 10.1, CH), 130.93 (d, J = 5.3), 130.43 
(d, J = 3.0), 130.16 (d, J = 12.4, CH), 120.07 (d, J = 84.6, Cq), 29.05 (d, J = 47.4, PCH2), 4.86 (d, J 
= 55.6, CH3)). LRMS (ES
+) m/z 607.13 [(M-H)+]. Anal. Calcd. (C41H38Br2OP2•2 C3H7NO): C, 
62.79; H, 5.39, Br, 18.99. Found: C, 62.70; H, 5.83; Br, 18.74. HPLC ≥ 95%. 
4,4'-bis((diphenylethylphosphonio)methyl)benzophenone dibromide (14). The reaction was 
carried out following the general procedure with ethyldiphenylphosphine. Compound 14 was 
obtained as an off-white solid (67%) following workup II procedure; mp 118–123 ºC with previous 
softening (DMF/toluene); 1H NMR (300 MHz, DMSO) δ 8.05 – 7.65 (m, 20H, ArH), 7.54 (d, J = 
7.8, 4H, ArH), 7.17 (m, 4H, ArH), 4.90 (d, J = 16.2, 4H, PhCH2P), 3.02 (m, 4H, PCH2CH3), 1.14 
(td, J = 7.4, 21, 6H, CH3).
 13C NMR (75 MHz, DMSO) δ 195.01 (CO), 136.56 (d, J = 3.7), 135.20 
(d, J = 2.1), 133.77 (d, J = 9.5, CH), 130.76 (d, J = 5.2), 130.34 (CH), 130.18 (CH), 117.91 (d, J = 
82.7, Cq), 27.11 (d, J = 45.7, PCH2), 12.64 (d, J = 50.6, PCH2), 5.97 (d, J = 4.7, CH3). LRMS (ES
+) 
m/z 635.18 [(M-H)+], 318.26 [M2+, 100%]. ESI-HRMS m/z 635.2628 (M-H)+(C43H41OP2 requires 
635.2627). HPLC = 92%. 
4,4'-bis((triphenylphosphonio)methyl)benzophenone dibromide (15).
47,48 The reaction was 
carried out following the general procedure with triphenylphosphine. Compound 15 was obtained as 
an off-white solid (66%) following workup II procedure; mp > 200 ºC (decomp.); 1H NMR (300 
MHz, DMSO) δ 8.30 – 7.61 (m, 30H, ArH), 7.52 (d, J = 7.8, 4H, ArH), 7.14 (d, J = 7.7, 4H, ArH), 
5.33 (d, J = 16.1, 4H, CH2). 
13C NMR (75 MHz, DMSO) δ 195.08 (CO), 136.81 (d, J = 3.7, Cq), 
135.60, 134.44 (d, J = 10.0), 133.47 (d, J = 8.4), 131.33 (d, J = 4.9), 130.56 (d, J = 12.5), 130.27 (d, 
J = 2.7), 117.93 (d, J = 85.9, Cq), 28.43 (d, J = 46.1, CH2). LRMS (ES
+) m/z 731.21 [(M-H)+], 366.3 
[M2+, 100%]. HPLC ≥ 95%. 
4,4'-bis((diphenyl-2-pyridylphosphonio)methyl)benzophenone dibromide (16). The reaction 
was carried out following the general procedure with diphenyl-2-pyridylphosphine. Compound 16 
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was obtained as a beige solid (69%) following workup II procedure; mp 175–178 ºC (decomp.); 1H 
NMR (300 MHz, DMSO) δ 9.03 (d, J = 4.5, 2H, ArH, 6-Hpyr), 8.21 (dt, J = 7.8, 6.1, 2H, ArH), 8.13 
– 7.98 (m, 2H, ArH), 7.92 (dd, J = 14.6, 6.1, 6H, ArH), 7.83 – 7.64 (m, 16H, ArH), 7.46 (d, J = 7.9, 
4H, ArH), 7.20 – 7.04 (m, 4H, ArH), 5.29 (d, J = 16.4, 4H, CH2).
 13C NMR (75 MHz, DMSO) δ 
195.01 (CO), 152.44 (d, J = 19.5), 144.04 (d, J = 116.4, Cq), 138.84 (d, J = 9.9), 136.65 (d, J = 3.7), 
135.61 (d, J = 2.7), 134.62 (d, J = 9.8, CH), 133.46 (d, J = 8.4), 132.17 (d, J = 23.8), 131.30 (d, J = 
5.5), 130.43 (d, J = 12.5, CH), 130.12 (d, J = 2.7), 128.99 (d, J = 3.2), 117.26 (d, J = 84.9, Cq), 
27.93 (d, J = 46.4, CH2). LRMS (ES
+) m/z 733.12 [(M-H)+], 366.89 [M2+, 100%]. Anal. Calcd. 
(C49H40Br2N2OP2): C, 65.79; H, 4.51, N, 3.13. Found: C, 65.98; H, 4.80; N, 3.20. 
4,4'-bis((diphenyl-o-tolylphosphonio)methyl)benzophenone dibromide (17). The reaction was 
carried out following the general procedure with diphenyl(o-tolyl)phosphine. Compound 17 was 
obtained as an off-white solid (55%) following workup II procedure; mp 255.9–262.7 ºC with 
previous softening (DMF/toluene); 1H NMR (300 MHz, CDCl3) δ 8.17 (br, 2H, ArH), 7.9 – 7.45 
(m, 26H, ArH), 7.22 (m, 8 H, ArH), 5.60 (d, J = 15.0, 4H, CH2), 1.99 (s, 6H, CH3).
 13C NMR (75 
MHz, CDCl3) δ 195.58 (CO), 143.50 (d, J = 8.4), 137.01 (d, J = 3.7), 136.81 (d, J = 10.9), 136.0 (d, 
J = 2.2), 135.45 (d, J = 2.4), 134.53 (d, J = 9.8), 133.82 (d, J = 11.0), 133.19 (d, J = 8.2), 132.14 (d, 
J = 5.4), 130.75 (d, J = 12.6), 130.53 (d, J = 2.4), 128.65, 117.93 (d, J = 84.7, Cq), 116.55 (d, J = 
83.2, Cq), 32.24 (d, J = 47.6, CH2), 23.29 (d, J = 4.4, CH3). LRMS (ES
+) m/z 759.35 [(M-H)+], 
380.1 [M2+, 100%]. ESI-HRMS m/z 759.2936 (M-H)+ (C53H45OP2 requires 759.2940). HPLC = 
92%. 
4,4'-bis((diphenyl-p-tolylphosphonio)methyl)benzophenone dibromide (18). The reaction was 
carried out following the general procedure with diphenyl(p-tolyl)phosphine. Compound 18 was 
obtained as an off-white solid (50%) following workup II procedure; mp 296.9–298.5 ºC 
(DMF/toluene); 1H NMR (300 MHz, CDCl3) δ 8.0 – 7.0 (m, 36H, ArH), 5.73 (br, 4H, CH2), 2.44 (s, 
6H, CH3). 
13C NMR (75 MHz, CDCl3) δ 194.92 (CO), 146.47 (d, J = 2.5), 135.0 (br), 134.86, 
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134.68 (d, J = 10.2, CH), 133.13 (d, J = 8.5), 132.29 (d, J = 5.0), 131.23 (d, J = 13.0), 130.36 (d, J 
= 12.5, CH), 118.29 (d, J = 86.0, Cq), 114.08 (d, J = 88.4, Cq), 31.24 (d, J = 46.1, CH2), 22.22 
(CH3). LRMS (ES
+) m/z 759.21 [(M-H)+], 380.24 [M2+, 100%]. ESI-HRMS m/z 759.2929 (M-H)+ 
(C53H45OP2 requires 759.2940). HPLC ≥ 95%. 
4,4'-bis((tri-2-furanylphosphonio)methyl)benzophenone dibromide (19). The reaction was 
carried out following the general procedure with tri-2-furylphosphine. Compound 19 was obtained 
as a beige solid (76%) following workup II procedure; mp 214.5–223.7 ºC with previous softening 
(DMF/toluene); 1H NMR (300 MHz, CDCl3) δ 8.03 (br m, 14H, ArH), 7.43 (m, 6H, ArH), 6.78 (br 
s, 6H, ArH, 4-Hfuranyl), 5.55 (br m, 4H, CH2). 
13C NMR (75 MHz, CDCl3) δ 195.21 (CO), 154.06 (d, 
J = 8.6, CH), 137.14 (d, J = 4.3, Cq), 133.33 (d, J = 22.0, CH), 131.86 (d, J = 6.3, CH), 131.28 (d, J 
= 9.9, Cq), 131.05 (d, J = 11.9, CH), 130.1 (d, J = 125.2, Cq), 114.26 (d, J = 10.0, CH), 32.54 (d, J = 
53.4, CH2). LRMS (ES
+) m/z 671.08 [(M-H)+], 336.0 [M2+, 100%]. ESI-HRMS m/z 671.1379 (M-
H)+( C39H29O7P2 requires 671.1383). HPLC ≥ 95%. 
Cultured Cells. Promastigotes from the Leishmania donovani strain MHOM/SD/00/1S-2D, 
its derived isogenic strain, 3-Luc, which expresses a C-terminal mutated form of luciferase 
(cytoplasmic luciferase), and L. pifanoi axenic amastigotes (MHOM/VE/60/Ltrod) were grown as 
described.29, 49 
Peritoneal macrophages from BALB/c mice were obtained by previous elicitation of the 
mouse by a single intraperitoneal injection of 1 mL of 3% sodium thioglycolate, four days priors to 
macrophage harvesting by peritoneal lavage.  
Unless otherwise stated, reagents were purchased from Sigma-España (Madrid, Spain). 
Propidium iodide, SYTOX Green, rhodamine 123 [2-(6-Amino-3-imino-3H-xanthen-9-yl)benzoic 
acid methyl ester, chloride] and DMNPE-luciferin [D-luciferin, 1-(4, 5-dimethoxy-2-nitrophenyl) 
ethyl ester] were purchase from Invitrogen (Barcelona, Spain). 
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Fluorescence and luminescence measurements were recorded in a Polarstar Galaxy 
microplate reader (BMG Labotechnologies, Offenburg, Germany), fitted with the corresponding 
optical setting, unless otherwise stated. 
Cytotoxic Activity Measurements. Promastigotes and amastigotes were harvested at late 
exponential phase, washed twice in Hanks’ buffer, supplemented with 10 mM D-glucose (pH 7.2) 
(HBSS-Glc) at 4 ºC, and resuspended in the same buffer at 2 × 107 cells/mL. These standard 
conditions were maintained for the rest of the experiments unless otherwise stated. Aliquots (120 
µL) of this cellular suspension were incubated with the drugs for 4 h, either at 25 ºC or 32 ºC for 
promastigotes and amastigotes, respectively. Afterwards, 20 µL aliquots of this suspension were 
taken, added to 1 mL HBSS-Glc and centrifuged to remove unbound reagent. Washed parasites 
were resuspended in 100 µL of their respective growth medium devoid of phenol red, transferred 
into a new 96-well microplate, and allowed to proliferate (48 h, 25 ºC for promastigotes; 96 h, 32 ºC 
for amastigotes). Finally, 100 µL of MTT solution (1 mg/mL) in HBSS-Glc were added, and 
substrate reduction allowed to proceed for 2 h at 25 ºC or 32 ºC for promastigotes or amastigotes, 
respectively. Precipitated formazan was solubilized by addition of 100 µL of 10% (w/v) SDS 
solution and read in a 450 Bio-Rad ELISA microplate reader equipped with a 600 nm filter.29 To 
measure the short-term effect, 100 µL (1.6 x 106 promastigotes) of the remaining parasites, were 
washed with 1 mL HBSS-Glc, resuspended and assayed for MTT reduction as above. 
The induction of apoptosis by 7 was monitored by analysis of the sub-G1 peak in parasites 
incubated overnight with different concentrations of 7. After the incubation, parasites were stained 
with 50 µg/mL propidium iodide (PI) and individual cellular fluorescence measured in a Beckman 
Coulter FC500 MPL cytofluorometer. As positive control for apoptosis induction, parasites were 
treated in identical conditions with 15 µM miltefosine (hexadecylphosphocholine).31 
BALB/c peritoneal macrophages were resuspended in their culture medium at a final density 
of 106 cells/mL, plated in a 96-well culture microplate (100 µL/well), and incubated with compound 
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7 for 24 h at 37 ºC. Cytotoxicity was assessed using the colorimetric MTT reduction assay and 
expressed as the percentage of the value obtained for control cells. 
Changes in Intracellular ATP Levels. The in vivo variation of intracellular ATP levels in 
L. donovani promastigotes was measured in 3-Luc parasites expressing a cytoplasmic form of 
Photinus pyralis luciferase.29 Briefly, the substrate for luciferase, DMNPE-luciferin [D-luciferin, 1-
(4, 5-dimethoxy-2-nitrophenyl) ethyl ester], was prepared as a 5 mM stock solution in DMSO. It 
was added to the 3-Luc promastigote suspension (2 × 107 cells/mL) in HBSS-Glc at a final 
concentration of 25 µM, and aliquots of this suspension were immediately distributed into a 96-well 
microplate (100 µL/well). Compound 7 was added once the luminescence reached a plateau. This 
point was considered as time zero, and its luminescence taken as 100%. Changes in luminescence 
were recorded for 80 min using a luminescence optics setting. The measurements were averaged 
every 4 s. In vitro inhibition of luciferase (EC 1.13.12.7) by the compound was tested as described29 
using a commercial purified enzyme (Roche Applied Sciences, Madrid, Spain).  
Plasma Membrane Permeabilization. It was assessed by the entrance of the vital dye 
SYTOX green (MW 600), according to the procedure described previously.50 Briefly, compound 7 
was added to L. donovani promastigotes in HBSS-Glc (2 × 107 promastigotes/mL) preincubated 
with 1 µM SYTOX green. Entrance of the dye into the intracellular compartment is only afforded 
through injured membranes, with lesions large enough to allow dye passage. The increase of 
fluorescence, due to binding of the dye to intracellular nucleic acids, was monitored using 485 and 
520 nm filters for excitation and emission wavelengths, respectively. Full permeation was 
considered as that achieved by 0.1% Triton X-100 (TX-100).  
Electron Microscopy. Promastigotes were incubated with compound 7 according to the 
standard procedure, washed twice in PBS, and fixed in 5% (w/v) glutaraldehyde in the same 
medium. Afterwards, parasites were included with 2.5% (w/v) OsO4 for 1 h, gradually dehydrated 
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in ethanol (30, 50, 70, 90 and 100% (v/v); 30 min each), and propylene oxide (1 h), embedded in 
Epon 812 resin, and observed in a Jeol-1230 electron microscope as described.50 
Effects on Mitochondrial Activity. Variation of the mitochondrial membrane potential 
(∆Ψm) of promastigotes was measured by rhodamine 123 accumulation.39 To this end, 
promastigotes were incubated in their growth medium with the leishmanicidal benzophenone-
derived bisphosphonium compounds at their respective LC50 overnight, and dye incorporation 
measured in a Beckman Coulter FC500 MPL cytofluorometer (excitation and emission wavelengths 
488 and 525 nm, respectively). Parasites either untreated, or fully depolarized by incubation with 1 
mM KCN, were used as controls. Following the same protocol, a more extensive range of 
concentrations was used to study the effect of compound 7 on rhodamine 123 accumulation. 
Oxygen consumption rates were measured in a Clark-oxygen electrode (Hansatech, 
KingsLynn, UK) at 25 ºC, using 1 mL of a promastigote suspension (108 cells/mL) in respiration 
buffer supplemented with 5 mM succinate and 1 mg/mL fatty acid free BSA as described.37 Cells 
were permeabilized with 60 µM digitonin, which allows a selective permeation of the plasma 
membrane but not of the inner mitochondrial membrane.51 Afterwards, 100 µM ADP was added to 
restore state 3 of respiration, and once a steady rate was reached, compound 7 was added, followed 
by a selective set of substrates and inhibitors specific for the different complexes of the respiratory 
chain, at concentrations stated in the corresponding figures.  
Statistical Analysis. Data represent the mean of triplicate samples ± S.D. LC50 values were 
calculated from the sigmoidal inhibition curves using the SigmaPlot 11.0 software. 
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Figure 1. Variation of intracellular ATP level assessed by in vivo luminescence of 3-Luc 
promastigotes after addition of compound 7. Promastigotes (2 × 107 cells/mL) were preloaded with 
25 µM DMNPE-luciferin; when luminescence signal reached a plateau luminescence was 
considered as 100% and compound 7 was added (t = 0). Variation in luminescence was normalized 
relative to the control untreated parasites. Compound 7 concentrations (µM): 0.6 (), 1.0 (), 2.5 
(), 8.0 (). 
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Figure 2. Electron microscopy of L. donovani promastigotes treated with compound 7. (A) Control 
parasites. (B) Parasites were incubated for 4h with 5 µM of 7, a concentration that caused ca 80% 
inhibition of proliferation. Mitochondrial kinetoplast was indicated by the arrow. Bar, 1 µm. 




Figure 3. Variation of ∆Ψm of L. donovani promastigotes monitored by rhodamine 123 
accumulation. Parasites treated with 7 overnight as well as control cells were loaded with 0.3 
µg/mL rhodamine 123 and fluorescence level measured by cytofluorometry. Compound 7 
concentration is shown at the side of each trace. Full depolarized parasites were obtained by 
incubation with 1 mM KCN. 


















Figure 4. Variation of oxygen consumption rates of L. donovani promastigotes by 7. Bar scales for 
oxygen concentration (Y axis) and time (X axis) are included. Oxygen consumption rates were 
calculated from the corresponding slopes of the traces. Arrows stand for the addition of the 
indicated substrates and inhibitors at their respective final concentrations as stated: 10 µM FCCP, 
60 µM digitonin, 100 µM ADP, 0.1 mM TMPD plus 1.7 mM ascorbate, 2 mM malonate, 6.7 α-
glycerophosphate (α-GP) and 1 µM antimycin A. (A) Intact parasites, (B and C) digitonin-
permeabilized promastigotes. 




Figure 5. Assessment by cytofluorometry of apoptosis in L. donovani promastigotes treated with 7. 
The presence of a sub-G1 peak, characteristic of the apoptotic cell population, was identified by 
nucleic acid staining with PI, and their percentage (D) indicated in each histogram  
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Scheme 1.
a  












a Reagents and conditions. (i) NBS, Benzoyl peroxide cat., CCl4, 80 ºC; (ii) R1R2R3P, DMF or 
toluene, 110 ºC. 




Scheme 2. Scheme of the respiratory chain in Leishmania with the specific substrates and inhibitors 
used in this study. Sites of electron feeding or inhibition are indicated by solid or dotted lines, 
respectively. UQ, ubiquinone; Cyt C, cytochrome c. 










I R = (Ph3)P+





III R = (Ph3)P+
IV   
Chart 1. Known triphenylphosphonium compounds with antischistosomal (I, III) or 
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LC50 (µM) % ∆Ψmc 










Miltefosine    12.50 ± 2.90 26.30 ± 3.40 75.00 
1 Me Me Me >50 >50 - 
2 Et Et Et >50 >50 - 
3 n-Pr n-Pr n-Pr >50 >50 - 
4 i-Pr i-Pr i-Pr >50 >50 - 
5 n-Bu n-Bu n-Bu >50 >50 - 
6 i-Bu i-Bu i-Bu >50 >50 - 
7 n-C5H11 n-C5H11 n-C5H11 1.09 ± 0.14 0.97 ± 0.01 48.00 
8 c-C6H11 c-C6H11 c-C6H11 3.30 ± 1.19 1.67 ± 0.06 42.00 
9 n-C8H17 n-C8H17 n-C8H17 5.66 ± 0.46 1.37 ± 0.05 10.80 
10 Me Me Ph >50 >50 - 
11 Et Et Ph >50 >50 - 
12 c-C6H11 c-C6H11 Ph 2.10 ± 0.84 1.45 ± 0.17 83.12 
13 Me Ph Ph 19.31 ± 0.64 1.64 ± 0.5 100.00 
14 Et Ph Ph 6.90 ± 0.50 14.01 ± 1.20 100.00 
15 Ph Ph Ph 2.73 ± 0.99 1.53 ± 0.03 67.25 
16 Ph Ph 2-pyridyl 3.03 ± 0.66 2.58 ± 0.30 100.00 
17 Ph Ph o-tolyl 1.90 ± 0.01 1.51 ± 0.05 55.75 
18 Ph Ph p-tolyl 1.20 ± 0.29 1.38 ± 0.02 53.25 
19 2-furanyl 2-furanyl 2-furanyl 18.12 ± 1.20 >50 - 
a Promastigotes of L. donovani strain MHOM/SD/00/1S-2D; b Amastigotes of L. pifanoi strain MHOM/VE/60/Ltrod. c 
Percentage of rhodamine 123 accumulated in the promastigote mitochondrion after overnight incubation at the 
respective LC50, relative to untreated cells. 
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